{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:06Z","timestamp":1790995146840,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2018,9,18]]},"abstract":"\n Background<\/jats:title>\n \n In statin trials, men and women derived similar relative risk reductions in cardiovascular events per 39\u00a0mg\/\n dL<\/jats:styled-content>\n low\u2010density lipoprotein cholesterol (\n LDL<\/jats:styled-content>\n \u2010C) reduction. We explored whether lower\n LDL<\/jats:styled-content>\n \u2010C levels and greater\n LDL<\/jats:styled-content>\n \u2010C percentage reductions than those achieved with statins are associated with reduced major adverse cardiovascular event (\n MACE<\/jats:styled-content>\n ) rates in women as well as men.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n Data pooled from 10 phase 3\n ODYSSEY<\/jats:styled-content>\n randomized trials (n=4983) comparing alirocumab with control (placebo\/ezetimibe) were assessed for association between 39\u00a0mg\/dL lower on\u2010treatment\n LDL<\/jats:styled-content>\n \u2010C and percentage\n LDL<\/jats:styled-content>\n \u2010C change from baseline, and\n MACE<\/jats:styled-content>\n risk by sex, using multivariable Cox regression. Mean baseline\n LDL<\/jats:styled-content>\n \u2010C was 135\u00a0mg\/dL (women) and 121\u00a0mg\/dL (men). Average on\u2010treatment\n LDL<\/jats:styled-content>\n \u2010C levels with alirocumab, ezetimibe, and placebo were 71, 114, and 134\u00a0mg\/dL, respectively, in women (n=1882) and 52, 93, and 122\u00a0mg\/dL, respectively, in men (n=3090). Overall, 36.5% and 58.7% of women and men, respectively, achieved on\u2010treatment\n LDL<\/jats:styled-content>\n \u2010C <50\u00a0mg\/dL. Each 39\u00a0mg\/dL lower\n LDL<\/jats:styled-content>\n \u2010C was associated with a 33% and 22%\u00a0lower risk of\n MACE<\/jats:styled-content>\n in women (\n P<\/jats:italic>\n =0.0209) and men (\n P<\/jats:italic>\n =0.0307), respectively, with no significant between\u2010sex difference (\n P<\/jats:italic>\n for heterogeneity=0.4597). Results were similar when analyzed per 50%\n LDL<\/jats:styled-content>\n \u2010C reduction, 24% (\n P<\/jats:italic>\n =0.1094) and 29% (\n P<\/jats:italic>\n =0.0125) lower\n MACE<\/jats:styled-content>\n risk in women and men, respectively (\n P<\/jats:italic>\n for heterogeneity=0.7499). Alirocumab was generally well tolerated in both sexes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The present analysis reinforces the notion that both sexes derive a similar cardiovascular benefit from\n LDL<\/jats:styled-content>\n \u2010C lowering. Although women had slightly higher on\u2010treatment\n LDL<\/jats:styled-content>\n \u2010C than men, both sexes showed a similar lower\n MACE<\/jats:styled-content>\n risk with lower\n LDL<\/jats:styled-content>\n \u2010C.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/jaha.118.009221","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T15:02:17Z","timestamp":1537110137000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Lower On\u2010Treatment Low\u2010Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials"],"prefix":"10.1161","volume":"7","author":[{"given":"Antonio J.","family":"Vallejo\u2010Vaz","sequence":"first","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention Department of Primary Care and Public Health Imperial College London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Columbia University New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Chicago Medicine Chicago IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus Aurora CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine Innovation Brigham and Women's Hospital Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Veronica","family":"Lee","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bessac","sequence":"additional","affiliation":[{"name":"Sanofi Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[{"name":"Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention Department of Primary Care and Public Health Imperial College London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.968792"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"e_1_3_2_7_2","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser U","year":"2017","unstructured":"Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, Luscher TF, Sinning D, Tokgozoglu L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL; European Society of Cardiology, European Atherosclerosis Society . European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38:2245\u20132255.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024604"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.037"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv028"},{"key":"e_1_3_2_17_2","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein JJ","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara\u2010Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","journal-title":"Eur Heart J"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.064"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006901"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000438"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.118.009221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:20:30Z","timestamp":1715599230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.118.009221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":26,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,9,18]]}},"alternative-id":["10.1161\/JAHA.118.009221"],"URL":"https:\/\/doi.org\/10.1161\/jaha.118.009221","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]},"assertion":[{"value":"2018-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e009221"}}